Results 31 to 40 of about 18,115 (178)

Regorafenib- associated panniculitis [PDF]

, 2016
Regorafenib is a second-generation multikinase inhibitor that is approved for the treatment of metastatic colon cancer and advanced gastrointestinal stromal tumors.
Patel, Anisha B, Aung, Phyu, Chockalingam, Ramya   +2 more
core   +1 more source

Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

Frontiers in Oncology, 2020
An increasing number of studies have shown that long non-coding RNA (lncRNA) dysregulation plays a fundamental role in the development of various cancers, including colon cancer.
Fang Wei, Mofei Wang, Zhen Li, Yong Wang, Yong Zhou   +4 more
doaj   +1 more source

Regorafenib suppresses sinusoidal obstruction syndrome in rats. [PDF]

, 2015
[Background]Sinusoidal obstruction syndrome (SOS), a form of drug-induced liver injury related to oxaliplatin treatment, is associated with postoperative morbidity after hepatectomy.
Okuno, Masayuki, Hatano, Etsuro, Taura, Kojiro, Miyagawa-Hayashino, Aya, Uemoto, Shinji, Nishio, Takahiro, Nakamura, Kojiro, Kasai, Yosuke, Seo, Satoru   +8 more
core   +1 more source

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment [PDF]

Clinical and Molecular Hepatology, 2020
Background/Aims Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients.
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim   +12 more
doaj   +1 more source

DataSheet1_Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer.docx

, 2023
Introduction: Colorectal cancer is one of the most prevalent life-threatening malignant tumors with high incidence and mortality. However, the efficacy of current therapeutic regimens is very limited.
Tao Yuan (443733), Weihua Wang (196992), Hong Zhu (109912), Qiaojun He (237893), Yue Liu (292931), Wencheng Kong (11434101), Bo Yang (104813), Ruilin Wu (7110221)   +7 more
core   +1 more source

The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib

Cell Death and Disease, 2021
Cytokeratin 19-positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype characterized by early recurrence and chemotherapy tolerance. However, there is no specific therapeutic option for CK19+ HCC. The correlation between tumor recurrence
Jianyong Zhuo, Di Lu, Zuyuan Lin, Xinyu Yang, Modan Yang, Jianguo Wang, Yaoye Tao, Xue Wen, Huihui Li, Zhengxing Lian, Beini Cen, Siyi Dong, Xuyong Wei, Haiyang Xie, Shusen Zheng, Youqing Shen, Xiao Xu   +16 more
doaj   +1 more source

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. [PDF]

PLoS ONE, 2018
Regorafenib has been demonstrated as effective in refractory metastatic colorectal cancer. Combination use with chemotherapy has not been reported. We examined the efficacy and safety of adding chemotherapy to Regorafenib for the treatment of metastatic ...
Chun-Yu Lin, Tseng-Hsi Lin, Chou-Chen Chen, Ming-Cheng Chen, Chou-Pin Chen   +4 more
doaj   +1 more source

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

, 2016
Background Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC).
Virginie Nerich, Marine Jary, Christophe Borg, Thierry Nguyen, Zaher Lakkis, Sabrina Lenoble, Fabien Calcagno, Stefano Kim, Samuel Limat   +8 more
core   +1 more source

Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer

, 2022
Regorafenib is a multikinase inhibitor. It is used for metastatic colorectal cancer (mCRC) treatment. It has a mild effect. Regorafenib outcomes, and side effects may vary across patients.
Celal Alandağ, Alandag, Celal, Karaman, ELANUR, Yuce, Elif, Elanur Karaman, Elif Yüce   +5 more
core   +1 more source

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

Journal for ImmunoTherapy of Cancer, 2020
Background and purpose Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain ...
Alexander Quaas, Lipika Goyal, Andrew X Zhu, Mark Cobbold, Dan G Duda, Rakesh K Jain, Kohei Shigeta, Aya Matsui, Hiroto Kikuchi, Sebastian Klein, Emilie Mamessier, Ivy X Chen, Shuichi Aoki, Shuji Kitahara, Koetsu Inoue, Ayako Shigeta, Tai Hato, Rakesh R Ramjiawan, Daniel Staiculescu, Dieter Zopf, Lukas Fiebig, Gabriela S Hobbs, Simona Dima, Irinel Popescu, Peigen Huang, Lance L Munn   +25 more
doaj   +1 more source